With Paz­dur prepar­ing to low­er the boom on its PD-1, Eli Lil­ly spells out the deep dis­count on of­fer

Eli Lil­ly’s crew is walk­ing in­to an ad­comm Thurs­day where the key de­ci­sion mak­er from the FDA — on­col­o­gy czar Richard Paz­dur — has clear­ly in­di­cat­ed he’s go­ing to fight to nix their ap­pli­ca­tion for the PD-1 can­di­date sin­til­imab. Now Eli Lil­ly is mak­ing a counter move, spelling out in de­tail just what they mean about their ear­li­er com­ments about dis­rupt­ing the huge check­point mar­ket with dis­count pric­ing for this drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER